Portal de investigação
Fibrosing ILD Biomarkers That Rule Acceleration (FIBRALUNG) -NCT05635032
Dados básicos
- Código:
- Estudo Observacional Académico (FIBRALUNG)
- Protocolo:
- Estudo Observacional Académico (FIBRALUNG)
- EUDRACT:
- NCT:
- NCT05635032
- Centro:
- Dotação:
- Ano de início:
- 2021
- Ano de conclusão:
Objectivos do projeto
Tipo de Estudo: Estudo Observacional – Iniciativa do Investigador; Subtipo: Coorte; Fase: Cross-sectional; Natureza do Promotor: Academia – Tipo não comercial; Tipo de Centro: Unicêntrico – Cuidados Secundários – Centro de Ensaio: CHUSJ – Doença investigada: Fibrose Pulmonar – Participantes recrutados: 819;
Documentos
- Não há documentos
Participantes
Unidades de investigação
Stakeholders - Promotores
Outputs do ensaio clínico
12-Gene Expression Signature: A Potential Key for Predicting Prognosis and Benefit to ACT for Resectable NSCLC Patients
Siqueira, A; (...); Leal, LF
Meeting Abstract. 2023
Atezolizumab in previously treated non-smallcell lung cancer patients
Serino, M; (...); Hespanhol, V
Meeting Abstract. 10.1183/13993003.congress-2021.PA2304. 2021
Clinical outcomes of patients with acute exacerbations in interstitial lung diseases
Meeting Abstract. 10.1183/13993003.congress-2022.4266. 2022
Coexistence of pleuroparenchymal fibroelastosis and hypersensitivity pneumonitis - analysis of prognostic impact
Meeting Abstract. 10.1183/13993003.congress-2022.4094. 2022
COVID-19 in interstitial lung diseases: are fibrotic ILDs associated with worse outcomes?
Meeting Abstract. 10.1183/13993003.congress-2022.3230. 2022
COVID-19 in Patients with Lung Cancer - Experience from a Thoracic Oncology Center
Coelho, D; (...); Fernandes, G
Meeting Abstract. 2021
Deciphering the genetic tapestry: Insights into sarcoidosis across diverse populations with the MESARGEN Consortium
Meeting Abstract. 10.1183/13993003.congress-2024.OA952. 2024
Deregulated immune cell recruitment orchestrated by c-MET impairs pulmonary inflammation and fibrosis
Article. 10.1186/s12931-024-02884-1. 2024
Diagnostic yield and safety of transbronchial lung cryobiopsy and surgical lung biopsy in interstitial lung diseases: a systematic review and meta-analysis
Rodrigues, I; (...); Bastos, H.
Article. 10.1183/16000617.0280-2021. 2022
Disease behaviour and prognostic factors in Hypersensitivity Pneumonitis with UIP-like pattern
Meeting Abstract. 10.1183/13993003.congress-2021.OA2970. 2021
Distinct TNF-alpha and HLA polymorphisms associate with fibrotic and non-fibrotic subtypes of hypersensitivity pneumonitis
Freitas, C; (...); Morais, A
Article. 10.1016/j.pulmoe.2021.08.013. 2023
Efficacy and Safety of Indwelling Catheter for Malignant Pleural Effusions Related to Timing of Cancer Therapy: A Systematic Review
Porcel, JM; (...); Botana-Rial, M
Review. 10.1016/j.arbres.2023.06.007. 2023
Efficacy of mycophenolate mofetil in fibrotic hypersensitivity pneumonitis treatment
Meeting Abstract. 10.1183/13993003.congress-2023.PA410. 2023
Evolution of fibrotic interstitial lung diseases (ILD) after COVID-19
Meeting Abstract. 10.1183/13993003.congress-2022.4172. 2022
Familial Pulmonary Fibrosis: experience from a tertiary hospital
Meeting Abstract. 10.1183/13993003.congress-2021.PA2370. 2021
Fungal stimulation induces a specific Th1-like immune response in hypersensitivity pneumonitis patients
Meeting Abstract. 10.1183/13993003.congress-2024.PA2454. 2024
Heterogeneous Streptomycin Resistance Level Among Mycobacterium tuberculosis Strains From the Same Transmission Cluster
Rocha, DMGC; (...); Osório, NS
Article. 10.3389/fmicb.2021.659545. 2021
Home environmental fungal exposure in patients with Hypersensitivity Pneumonitis
Meeting Abstract. 10.1183/13993003.congress-2024.PA1581. 2024
Home environmental fungal exposure in patients with Hypersensitivity Pneumonitis - pilot analysis
Meeting Abstract. 10.1183/13993003.congress-2022.4281. 2022
Hypersensitivity Pneumonitis with and without Autoimmune Features: a comparative analysis at diagnosis
Meeting Abstract. 10.1183/13993003.congress-2024.PA1573. 2024
Immune-Related Adverse Effects of Immunotherapy in Patients With Advanced Non-Small Cell Lung Carcinoma
Freitas, C; (...); Fernandes, G
Meeting Abstract. 2021
Immunotherapy in metastatic non-small cell lung cancer: EPSILoN as a prognostic score
Valente, MCA; (...); Hespanhol, V
Meeting Abstract. 10.1183/13993003.congress-2022.3572. 2022
LUNG CARCINOID TUMORS: 10 YEARS OF EXPERIENCE
GUERRA, S. I.; (...); ARAUJO, D.
Meeting Abstract. 10.1016/j.chest.2021.12.338. 2022
Lymphangioleiomyomatosis - experience of a university hospital
Meeting Abstract. 10.1183/13993003.congress-2021.PA2371. 2021
Management of Coronavirus Disease 2019 Patients With Lung Cancer: Experience From a Thoracic Oncology Center
Coelho, DB; (...); Fernandes, MGO
Article. 10.3389/fmolb.2021.639676. 2021
Metabolic regulation of granulomatous inflammation by tryptophan catabolism
Meeting Abstract. 10.1183/13993003.congress-2024.PA2478. 2024
Modified Glasgow Prognostic Score - a predictor of survival in malignant pleural effusion
Martins, B; (...); Novais-Bastos, H
Meeting Abstract. 10.1183/13993003.congress-2021.PA3102. 2021
Monocyte/macrophage axis as potential drivers of Progressive Fibrosing Hypersensitivity Pneumonitis
Meeting Abstract. 10.1183/13993003.congress-2023.PA1164. 2023
Mortality risk prediction with ILD-GAP index in a fibrotic hypersensitivity pneumonitis cohort
Almeida, LM; (...); Morais, A
Article. 10.1177/17534666221135316. 2022
Mortality risk prediction with ILD-GAP index in a portuguese chronic hypersensitivity pneumonitis cohort
Meeting Abstract. 10.1183/13993003.congress-2021.PA2249. 2021
OBSTRUCTIVE SLEEP APNEA IN NON-IPF FIBROTIC ILD PATIENTS: WHO, HOW AND WHAT SHOULD WE OFFER?
Meeting Abstract. 2024
Pentraxin 3 Inhibits Complement-driven Macrophage Activation to Restrain Granuloma Formation in Sarcoidosis
Gonçales, RA; (...); Carvalho, A
Article. 10.1164/rccm.202112-2771OC. 2022
Pleuroparenchymal fibroelastosis as a complication of chemotherapy: A case report
Vieira, ACR; (...); Morais, A
Article. 10.3892/mco.2022.2504. 2022
Polymorphisms and haplotypes of TOLLIP and MUC5B are associated with susceptibility and survival in patients with fibrotic hypersensitivity pneumonitis
Article. 10.1016/j.pulmoe.2024.01.002. 2024
PREDICTIVE BIOMARKERS OF SEVERE IMMUNE-RELATED ADVERSE EVENTS IN NON-SMALL CELL LUNG CANCER
Magalhaes Ferreira, P.; (...); Hespanhol, V.
Meeting Abstract. 10.1016/j.chest.2021.12.341. 2022
Predictive value of common genetic variants in idiopathic pulmonary fibrosis survival
Mota, PC; (...); Morais, A
Article. 10.1007/s00109-022-02242-y. 2022
Predictive value of common genetic variants in idiopathic pulmonary fibrosis survival.
Article. 2022
Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors
Serino M.; (...); Hespanhol V.
Article. 10.1016/j.pulmoe.2022.03.003. 2024
Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors.
Article. 2024
Predictors of lung entrapment in malignant pleural effusion
Article. 10.1016/j.pulmoe.2022.08.001. 2024
PREDICTORS OF LUNG ENTRAPMENT IN PATIENTS WITH MALIGNANT PLEURAL EFFUSION
Meeting Abstract. 10.1016/j.chest.2021.12.311. 2022
PREDICTORS OF OVERALL SURVIVAL IN PATIENTS WITH MALIGNANT PLEURAL EFFUSION
Meeting Abstract. 10.1016/j.chest.2021.12.310. 2022
Predictors of pneumothorax after transbronchial lung cryobiopsy for diagnosis of interstitial lung diseases
Meeting Abstract. 10.1183/13993003.congress-2021.PA852. 2021
Predictors of survival and technical success of bronchoscopic interventions in malignant airway obstruction
Article. 10.21037/jtd-21-1393. 2021
Pulmonary Emphysema Regional Distribution and Extent Assessed by Chest Computed Tomography Is Associated With Pulmonary Function Impairment in Patients With COPD
Gomes, P; (...); Carvalho, ARS
Article. 10.3389/fmed.2021.705184. 2021
Reproducibility of a 12-gene panel and development of user-friendly nomogram-based calculator for clinical management of surgically resected non-small cell lung cancer patients.
Meeting Abstract. 2021
Reproducibility of a 12-gene set for predicting outcome and benefit from ACT in earlystage NSCLC patients
Meeting Abstract. 10.1183/13993003.congress-2023.OA1451. 2023
Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer
Fernandes, MGO; (...); Hespanhol, V
Article. 10.3389/fonc.2021.602924. 2021
Risk Factors for Acute Exacerbations of Fibrotic Hypersensitivity Pneumonitis-Is Exposure a Trigger That We're Missing?
Coelho, DB; (...); Melo, N
Letter. 10.1016/j.arbres.2022.07.004. 2023
RISK FACTORS FOR ACUTE EXACERBATIONS OF HYPERSENSITIVITY PNEUMONITIS
Meeting Abstract. 10.1016/j.chest.2021.12.280. 2022
Serum metalloproteinase 7 as a biomarker of progressive pulmonary fibrosis
Araújo, M; (...); Morais, A
Meeting Abstract. 10.1183/13993003.congress-2023.PA1155. 2023
Serum metalloproteinase-7 as a biomarker of progressive pulmonary fibrosis
Article. 10.1183/23120541.00553-2024. 2024
SOMATOSTATIN ANALOGS IN THE TREATMENT OF LUNG CARCINOID TUMORS: AN EXPERIENCE OF A LARGE CENTER
Valente, A.; (...); Queiroga, H.
Meeting Abstract. 10.1016/j.chest.2021.12.347. 2022
Spread through air spaces prognostic value in adenocarcinoma
Meeting Abstract. 10.1183/13993003.congress-2023.PA2214. 2023
The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting
Santos, G; (...); Morais, A
Article. 10.1016/j.pupt.2023.102261. 2023
The role of interventional bronchoscopy in the management of post-intubation tracheal stenosis: A 20-year experience
Freitas, C; (...); Magalhaes, A
Article. 10.1016/j.pulmoe.2019.12.004. 2021
The Role of Ultrasonography in the Diagnosis and Decision Algorithm for the Management of Pneumothorax after Transbronchial Lung Cryobiopsy
Coelho, DB; (...); Bastos, H.
Article. 10.1159/000518140. 2021
Transbronchial lung cryobiopsy for the diagnosis of Fibrotic Hypersensitivity Pneumonitis
Meeting Abstract. 10.1183/13993003.congress-2023.PA2919. 2023
Unveiling common molecular pathways linked to ILDs with progressive fibrosing phenotype: the role of MUC5B promoter variants
Meeting Abstract. 10.1183/13993003.congress-2023.OA854. 2023
Validation of a 5-gene signature for predicting outcomes in early-stage NSCLC patients
Meeting Abstract. 10.1183/13993003.congress-2023.OA1449. 2023
